JUVE Comment

This well-positioned French boutique around French lawyer and UK-qualified solicitor Denis Schertenleib is bearing on the French market leaders in its pharma and telecommunication cases. Schertenleib stands out from its competitors in that it has recently expanded its client relationships in a dynamic way. In doing so, the firm has enhanced its presence in numerous high-profile cases against the French market leaders. The Paris boutique enjoys an excellent reputation for its litigation for generics companies. Regular clients include Mylan and Sandoz, which the firm represents on an ongoing basis in numerous cases.

With litigation for TCL against Philips, the team carved out a name for itself in telecommunications proceedings – especially concerning SEPs and FRAND licensing. This attracted new clients. The firm also saw dynamic personnel growth and is now training up two more young associates.

Strengths

In-depth knowledge of the pharma/generics market.

European strategy

The small outfit has good connections to boutiques and large firms in other important European markets who recommend it for high-stakes cases. Thanks to its experience in numerous major proceedings, the dynamic patent litigation firm makes a flexible partner for UK, Dutch or German law firms. Most recently, for example, the firm worked closely with Kirkland & Ellis’ UK team in several proceedings. With legal qualifications in France and the UK, the name partner personifies the firm’s understanding of the pan-European connections involved in patent litigation.

Recommended individuals

Denis Schertenleib (“very good litigator with a lot of cases,” “exceptional work for TCL,” competitors)

Team

2 partners, 6 associates

Specialties

Specialists for patent litigation in all technical fields.

Clients

Litigation: TCL (claimant) against Phillips on SEPs; Mylan and Sandoz (both defendant) against MSD on an SPC on ezetimibe/simvastatine (Supreme Court); Mylan (defendant) against Allergan on bimatoprost; Mylan (defendant) against Novartis on Everolimus; Mylan (defendant) against Eli Lilly over pemetrexed; Zentiva (defendant) against Novartis on Everolimus; Biogen (defendant) against Fresenius on a biosimilar; Amgen (Claimant) against Sanofi on an antibody patent; Royalty Pharma (claimant) against INPI on 5 SPCs; Filorga (defendant) against Teoxane on know-how and trade secrets.